Prostaglandin‐E1 infusion in persistent pulmonary hypertension of the newborn

Background Neonates with persistent pulmonary hypertension of the newborn (PPHN) can present with hypoxia and right ventricular dysfunction with resultant inadequate oxygen delivery and end‐organ damage. This study describes the use of prostaglandin‐E1 (PGE) for ductal patency to preserve right ventricular systolic function and limit afterload in newborns with PPHN. Methods This is a retrospective cohort study that follows the hemodynamics, markers of end‐organ perfusion, length of therapeutics, and echocardiographic variables of 57 newborns who used prostglandin‐E1 in the setting of PPHN. Results Tachycardia, lactic acidosis, and supplemental oxygen use improved following PGE initiation. Fractional area change (FAC), to assess right ventricular systolic function, and pulmonary arterial acceleration time indexed to right ventricular ejection time (PAAT/RVET), to assess right ventricular afterload, also improved over three time points relative to PGE use (before, during, and after). Conclusions Overall, we described the safety and utility of PGE in newborns with severe PPHN for stabilization while allowing natural disease progression.